GFAP and chronic kidney disease: Specifically, we observed significant interactions between IL‐6 and chronic kidney disease in relation to NfL (β 0.02, 95% CI 0.02–0.03, p < 0.001), between IL‐6 and cerebrovascular disease in relation to p‐tau181 (β 0.04, 95% CI 0.02–0.06, p 0.001) and GFAP (β 0.02, 95% CI 0.01–0.03, p 0.001) and between IL‐6 and anemia in relation to p‐tau181 (β 0.02, 95% CI 0.01–0.03, p 0.003), NfL (β 0.02, 95% CI 0.01–0.03, p < 0.001) and GFAP (β 0.01, 95% CI 0.00–0.02, p 0.001).